The Metropolitan Opera’s recent announcement that it would produce the “The Death of Klinghoffer” led to a nasty, noisy, public debate focused on charges of antisemitism. Some music journalists reveled in the attention and in the moment of relevance for a 400-year-old form. Cambridge critic Rachel Yurman, however, was incensed by the assault, and embarrassed by what she terms the “willful ignorance of those who ranted while freely admitting that they had never seen the work in question.”
Cambridge-Paris Ariana Pharma reports that it has joined the WIN Consortium as an official technology partner. The Consortium (Worldwide Innovative Networking in personalized cancer medicine) is a global collaboration of 40 leading organizations whose aim is to develop more effective cancer diagnostics and therapeutics, shorten clinical trial timelines and reduce the overall cost of cancer care.